Cold Kit PSMA PET Imaging: Phase I study of (68)Ga-THP-PSMA PET/CT in patients with prostate cancer

Objectives: Ga-68 labelled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as (68)Ga-HBED-PSMA-11, are promising small molecules for targeting prostate cancer. A new radiopharmaceutical (68)Ga-THP-PSMA has a simplified design for one-step kit-based radiolabelling. It features the tris(hydroxypyridinone) (THP) ligand, which complexes (68)Ga3+ rapidly at low concentration, room temperature and over a wide pH range, enabling direct elution from a (68)Ge/(68)Ga generator into a lyophilized kit in one-step without manipulation. This Phase I study aimed to assess the safety and biodistribution of (68)Ga-THP-PSMA. Methods: Cohort A: 8 patients with proven prostate cancer scheduled to undergo prostatectomy underwent PET/CT following administration of (68)Ga-THP-PSMA (Gleason score 7-10; PSA mean 7.8, range 5.4-10.6). All patients proceeded to prostatectomy (7 with pelvic nodal dissection). Dosimetry was performed with OLINDA/EXM from multi-time point PET imaging. Cohort B: 6 patients with a positive (68)Ga-HBED-PSMA-11 PET/CT underwent comparative (68)Ga-THP-PSMA scan. All patients were followed to evaluate for adverse events. Results: No adverse events occurred. Cohort A: Six of 8 patients had focal uptake in the prostate (at 2 h, average SUVmax 5.1, range 2.4-9.2) with correlative 3+ staining on PSMA immunohistochemistry on prostatectomy specimens. The two (68)Ga-THP-PSMA negative scans had only 1+/2+ staining. The mean effective dose was 2.07E-02 mSv/MBq. Cohort B: (68)Ga-THP-PSMA had lower physiologic background uptake compared to (68)Ga-HBED-PSMA-11 (parotid: mean SUVmax 3.6 compared to 19.2, liver: 2.7 to 6.3, spleen 2.7 to 10.5, p<0.001 for all). In 5 of 6 patients there was concordance in the number of metastases identified with (68)Ga-HBED-PSMA-11 and (68)Ga-THP-PSMA. 13 of 15 nodal abnormalities were sub-centimetre. In 22 malignant lesions, tumor-to-liver contrast was similar on THP-PSMA compared to HBED-PSMA (4.7 to 5.4, P = 0.15) despite higher SUVmax with HBED-PSMA (30.3 to 10.7, p<0.01). Conclusion:(68)Ga-THP-PSMA is safe with favourable biodistribution for clinical imaging. Observed focal uptake in the prostate localized to PSMA-expressing malignant tissue on histopathology. Metastatic PSMA-avid foci are also visualized with (68)Ga-THP-PSMA PET. Single step production from a GMP cold kit may enable rapid adoption.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Oct 06 [Epub ahead of print]

Michael S Hofman, Peter Eu, Price Jackson, Emily Hong, David Binns, Amir Iravani, Declan Murphy, Catherine Mitchell, Shankar Siva, Rodney J Hicks, Jennifer D Young, Philip Blower, Gregory E Mullen

Peter MacCallum Cancer Centre, Australia., King's College London, United Kingdom.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe